[Precision medicine in rearranged ALK NSCLC: a case report.]

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) is a leading solid tumor where precision medicine has been successfully applied.
• Understanding the molecular drivers of NSCLC has led to targeted therapies for specific genetic mutations.
• Anaplastic lymphoma kinase (ALK) gene rearrangement is a key target in advanced NSCLC, particularly in adenocarcinomas.

Observation:

• The ATLAS IALSC guidelines recommend ALK gene rearrangement screening for all advanced NSCLC patients.
• Next-generation sequencing (NGS) panels are increasingly used for comprehensive genetic profiling of NSCLC.
• Liquid biopsy offers a non-invasive approach for obtaining tumor genetic information.

Findings:

• NGS panels applied to liquid biopsy are a powerful tool for genetic profiling in NSCLC.
• Liquid biopsy provides clinically relevant information for patients with ALK-translocated NSCLC.
• This non-invasive method aids in defining therapeutic strategies for NSCLC patients with ALK rearrangements.

Implications:

• Liquid biopsy facilitates non-invasive detection of actionable mutations like ALK rearrangements in NSCLC.
• This approach supports personalized treatment selection and clinical trial enrollment for NSCLC patients.
• Enhanced genetic profiling through liquid biopsy improves the management of advanced NSCLC.